TTR and myelodysplastic syndrome: Moreover, DNA methyltransferase enzyme DNMT3A, a DNA methylation regulatory gene whose mutation was an adverse prognostic biomarker in both AML and MDS patients, was detected to be associated with low transthyretin in our cohort (38, 39).